About the Discovery Fast Track Challenge
The Discovery Fast Track Challenge recognises and rewards innovative concepts, discoveries and research by investigators at research institutions, colleges and universities. Winning investigators will collaborate with a team of our scientists to screen their target of interest to put their innovative research concept on an accelerated drug discovery path. We will provide state-of-the-art capabilities and scientific expertise as well as funding of up to $75,000AUD to support the collaboration. Research is conducted through truly integrated teams with work being carried out at GSK and the academic lab. Successful projects will get access to tool compounds that will assist future research. In addition, promising results may also lead to an opportunity for the investigator and institution to form a further collaboration that can lead to creating a novel medicine with the Discovery Partnerships for Academia (DPAc) group. To date 12 of our Discovery Fast Track challenges have received tool compounds and we have initiated several further DPAc collaborations.
DPAc represents an innovative approach to early drug discovery. The concept is simple but powerful: bring together the insight and deep scientific expertise of the academic world with the drug discovery expertise of GSK to establish truly integrated collaborations that can translate innovative research into medicines that benefit patients. GSK drug discovery experts and innovative academic scientists operate as a joint team, working towards common goals with open sharing of information.
GSK’s Discovery Fast Track is designed to initiate rapid collaborations to identify high quality tool compounds that academic researchers may use to deepen the understanding of biological mechanisms and increase the likelihood of success of generating translational biology that can ultimately lead to a novel therapy.
In some cases, progress made through Discovery Fast Track will lead to the formation of a full DPAc collaboration which if successful, may go all the way to a medicine link. GSK will provide financial rewards as pre-defined pre-clinical and clinical milestones occur. In cases where a project leads to the successful launch of a medicine, financial returns will be shared through royalty payments. GSK’s experienced DPAc scientists co-lead these collaborations and co-ordinate the application of GSK’s deep drug discovery and science capability onto each project.